{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:37:56Z","timestamp":1793284676751,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Clinical Investigator Research Award funded by the Crohn\u2019s and Colitis Foundation","award":["#878246"],"award-info":[{"award-number":["#878246"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to assess the risk of serious infections in patients with inflammatory bowel disease (IBD) exposed to different advanced therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We linked nationwide registers and compared rates of incident serious infections in patients with Crohn\u2019s disease (CD) and ulcerative colitis (UC) exposed to medical therapies versus matched general population comparators during 2007-2023. We 1:1 propensity score-matched individuals with IBD to compare infection risk across therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 55\u2009866 patients with IBD na\u00efve to immunomodulators (IMM) and advanced therapies, 20\u2009392 exposed to IMM, 15\u2009973 to anti-tumor necrosis factor (anti-TNF), 9035 to IMM with anti-TNF, 3948 to vedolizumab, 2926 to ustekinumab, 659 to tofacitinib, 987 to upadacitinib, 262 to filgotinib, and 163 to risankizumab with 987\u2009366 matched comparators with up to 18\u2009years of follow-up. Compared to the general population (incidence rate range 0.39-1.13 per 100 person-years [PY]), patients with IBD had a higher incidence of serious infections (na\u00efve 2.31 per 100 PY; adjusted hazard ratio [aHR] 1.89, 95% confidence interval [CI] 1.84-1.94), IMM 3.27 per 100 PY (aHR 4.45, 95% CI 4.24-4.66), and advanced therapies 3.14-8.10 per 100 PY (aHR 3.45-10.55, 95% CI 3.04-26.65). Relative risks were elevated in the pediatric population, and for opportunistic and gastrointestinal infections. No differences in infection rates were observed in propensity score-matched comparisons of different advanced therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with IBD were at an increased risk of infections, even among those na\u00efve to IMM and advanced therapies. There was no significant difference in the risk of infections across advanced therapy exposures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf229","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:06:38Z","timestamp":1765544798000},"source":"Crossref","is-referenced-by-count":8,"title":["Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: a nationwide cohort study"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-7790","authenticated-orcid":false,"given":"Jordan","family":"Axelrad","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-4982","authenticated-orcid":false,"given":"Anders","family":"Forss","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Gastroenterology, Gastroenterology Unit, Dermatovenereology and Rheumatology, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9006-2835","authenticated-orcid":false,"given":"Jonas","family":"S\u00f6derling","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-8713","authenticated-orcid":false,"given":"Karl","family":"M\u00e5rild","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy , Gothenburg,","place":["Sweden"]},{"name":"Department of Pediatrics, Queen Silvia Children\u2019s Hospital , Gothenburg,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Naucler","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Infectious Diseases, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F","family":"Ludvigsson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Pediatrics, \u00d6rebro University Hospital, \u00d6rebro University , \u00d6rebro,","place":["Sweden"]},{"name":"Department of Medicine, Columbia University College of Physicians and Surgeons , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ol\u00e9n","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Pediatric Gastroenterology and Nutrition, Sachs\u2019 Children and Youth Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"; SWIBREG Study Group\u2020","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Myrelid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hjortswang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Strid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"J\u00e4ghult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nordenvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rejler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Grip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika L","family":"Fagerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Hreinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026021619071210500_jjaf229-B1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/gutjnl-2018-317572","article-title":"Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014","volume":"69","author":"Ol\u00e9n","year":"2020","journal-title":"Gut"},{"key":"2026021619071210500_jjaf229-B3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/j.gastro.2018.10.028","article-title":"Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population","volume":"156","author":"Ol\u00e9n","year":"2019","journal-title":"Gastroenterology"},{"key":"2026021619071210500_jjaf229-B4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2021.06.076","article-title":"Serious infections in pediatric inflammatory bowel disease 2002-2017\u2013a nationwide cohort study","volume":"238","author":"Ludvigsson","year":"2021","journal-title":"J Pediatr"},{"key":"2026021619071210500_jjaf229-B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ibd\/izac097","article-title":"The risk of serious infections before and after anti-TNF therapy in inflammatory bowel disease: a retrospective cohort study","volume":"29","author":"Holmgren","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026021619071210500_jjaf229-B6","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/00365521.2021.1924259","article-title":"Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002-2017","volume":"56","author":"Ludvigsson","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"2026021619071210500_jjaf229-B8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cgh.2023.10.013","article-title":"Histologic activity in inflammatory bowel disease and risk of serious infections: a nationwide study","volume":"22","author":"M\u00e5rild","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B11","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"2026021619071210500_jjaf229-B12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREATTM registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B13","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","article-title":"Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases","volume":"20","author":"Cheng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B14","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026021619071210500_jjaf229-B15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/apt.15680","article-title":"Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study","volume":"51","author":"Hup\u00e9","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021619071210500_jjaf229-B16","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1097\/MEG.0000000000002166","article-title":"Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease","volume":"33","author":"Innocenti","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.12.030","article-title":"Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease","volume":"20","author":"Kirchgesner","year":"2022","journal-title":"Clin Gastroenterol \u00adHepatol"},{"key":"2026021619071210500_jjaf229-B18","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cgh.2020.10.003","article-title":"Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis","volume":"20","author":"Lukin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/apt.16193","article-title":"Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers","volume":"53","author":"Rundquist","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021619071210500_jjaf229-B21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.cgh.2021.07.038","article-title":"Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B22","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor \u03b1 antagonists vs vedolizumab in patients with inflammatory bowel diseases","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B23","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.14309\/ajg.0000000000002961","article-title":"Comparative risk of serious infection with vedolizumab vs anti-tumor necrosis factor in inflammatory bowel disease: results from nationwide Swedish registers","volume":"119","author":"Karlqvist","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10654-025-01226-9","article-title":"The healthcare system in Sweden","volume":"40","author":"Ludvigsson","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"2026021619071210500_jjaf229-B25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026021619071210500_jjaf229-B26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/00365521.2019.1660799","article-title":"Swedish Inflammatory Bowel Disease Register (SWIBREG) \u2013 a nationwide quality register","volume":"54","author":"Ludvigsson","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026021619071210500_jjaf229-B28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026021619071210500_jjaf229-B29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2026021619071210500_jjaf229-B30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CLEP.S191914","article-title":"Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)","volume":"11","author":"Ludvigsson","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026021619071210500_jjaf229-B31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2026021619071210500_jjaf229-B32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00365521.2016.1246605","article-title":"Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG)","volume":"52","author":"Jakobsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S2468-1253(20)30267-3","article-title":"Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden","volume":"5","author":"Nguyen","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026021619071210500_jjaf229-B34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/CLEP.S358031","article-title":"Identification of childhood-onset inflammatory bowel disease in Swedish healthcare registers: a validation study","volume":"14","author":"Mouratidou","year":"2022","journal-title":"Clin Epidemiol"},{"key":"2026021619071210500_jjaf229-B35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/00365521.2020.1740778","article-title":"The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register","volume":"55","author":"Shrestha","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2026021619071210500_jjaf229-B36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","volume":"17","author":"Solitano","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026021619071210500_jjaf229-B37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/apt.17386","article-title":"Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis","volume":"57","author":"Taxonera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021619071210500_jjaf229-B38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/ecco-jcc\/jjac133","article-title":"Opportunistic infections in patients with inflammatory bowel disease treated with advanced therapies: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Olivera","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026021619071210500_jjaf229-B39","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ecco-jcc\/jjae029","article-title":"The epidemiology of inflammatory bowel diseases during the COVID-19 pandemic: comparison of two nationwide cohorts","volume":"18","author":"Atia","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026021619071210500_jjaf229-B40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12049","article-title":"Inflammatory bowel disease and risk of severe COVID-19: a nationwide population-based cohort study in Sweden","volume":"9","author":"Ludvigsson","year":"2021","journal-title":"United European Gastroenterol J"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf229\/65900948\/jjaf229.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf229\/65900948\/jjaf229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/2\/jjaf229\/65900948\/jjaf229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:07:24Z","timestamp":1771286844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf229\/8380351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf229","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,15]]},"article-number":"jjaf229"}}